Two Sigma Investments
KLRS

Two Sigma Investments’s Kalaris Therapeutics KLRS Stock Holding History

Two Sigma Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Buy
30,650
+2,891
+10% +$25.7K ﹤0.01% 4301
2025
Q4 		$234K Buy
+27,759
New +$177K ﹤0.01% 3698
2025
Q1 		– Sell
-11,591
Closed -$112K – 3572
2024
Q4 		$112K Sell
11,591
-1,242
-10% -$18.8K ﹤0.01% 2954
2024
Q3 		$239K Sell
12,833
-2,470
-16% -$43.2K ﹤0.01% 2754
2024
Q2 		$255K Buy
15,303
+1,484
+11% +$26.2K ﹤0.01% 2654
2024
Q1 		$240K Buy
13,819
+2,317
+20% +$37.8K ﹤0.01% 2646
2023
Q4 		$180K Buy
11,502
+10,005
+668% +$395K ﹤0.01% 2859
2023
Q3 		$74K Buy
+1,497
New +$102K ﹤0.01% 2776
2022
Q3 		– Sell
-3,393
Closed -$304K – 2899
2022
Q2 		$304K Sell
3,393
-1,643
-33% -$172K ﹤0.01% 2023
2022
Q1 		$782K Buy
5,036
+1,190
+31% +$237K ﹤0.01% 1812
2021
Q4 		$1.15M Buy
3,846
+2,411
+168% +$1.12M ﹤0.01% 2417
2021
Q3 		$827K Sell
1,435
-244
-15% -$113K ﹤0.01% 2792
2021
Q2 		$762K Buy
1,679
+122
+8% +$63K ﹤0.01% 2729
2021
Q1 		$838K Buy
+1,557
New +$1.31M ﹤0.01% 2477

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Two Sigma Investments's KLRS Position: Q1 2026 in Review

Two Sigma Investments increased its Kalaris Therapeutics (KLRS) stake by 10% in Q1 2026, buying an estimated $25.7K and bringing the position to 30,650 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #4301.

Two Sigma Investments first reported a position in KLRS in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.15M in Q4 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Two Sigma Investments held 30,650 shares of Kalaris Therapeutics worth $177K as of Q1 2026.
  • Two Sigma Investments bought 2,891 Kalaris Therapeutics shares in Q1 2026, an estimated $25.7K.
  • Kalaris Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4301 holding.
  • Two Sigma Investments first reported a position in Kalaris Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • Two Sigma Investments's Kalaris Therapeutics position peaked at $1.15M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.